Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Qualit-E-SpeakPharma-Insert
    X

    Find drug development pipeline and deal Updates information

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              Sierra Oncology

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              Attacking drug-resistant tumors with Sierra’s struggling CHK1 blocker

              Contact the Supplier

              Lead Product(s): SRA737,Momelotinib,Aphidicolin

              Therapeutic Area: Oncology

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 12, 2020

              Details:

              Scientists found that combining the drug with another protein inhibitor leads to insurmountable DNA damage that causes cancer cells to die.

              IMV

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              Clinical Translational Data Supports DPX-Survivac Mechanism of Action

              Contact the Supplier

              Lead Product(s): DPX-Survivac

              Therapeutic Area: Oncology

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 04, 2020

              Details:

              DPX-Survivac generated survivin-specific T cells in the blood of 80% of patients sampled.

              PharmaCompass__DigitalAd